Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY2 | P41231 | 14/20 | 0.76 |
| ▸ | P2RY4 | P51582 | 9/20 | 0.76 |
| ▸ | P2RY6 | Q15077 | 7/20 | 0.75 |
| ▸ | P2RY14 | Q15391 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1620404 | 0.91 | P2RY2 (0.78) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL1620405 | 0.91 | P2RY2 (0.78) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL1996226 | 0.91 | P2RY2 (0.76) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL4575993 | 0.91 | P2RY2 (0.79) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL3502216 | 0.91 | P2RY2 (0.76) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL23705843 | 0.91 | P2RY2 (0.76) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL1230649 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 | |
| SCHEMBL28484026 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL5960971 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 | |
| Uridine Triphosphate SCHEMBL29239784 | 0.90 | P2RY2 (0.92) | P2RY2P2RY4P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | MODERNATX INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-20250074962-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | ARES CAPITAL CORPORATION, AS AGENT | 2025-03-06 | — | — | US | disclosed |
| US-20250018062-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | MODERNA TX INC (US) | 2025-01-16 | — | — | US | disclosed |
| US-20240409597-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-12-12 | — | — | US | disclosed |
| US-20240327476-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | ARES CAPITAL CORPORATION, AS AGENT | 2024-10-03 | — | — | US | disclosed |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2024-04-25 | — | — | US | disclosed |
| US-11564998-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | MODERNATX, INC. (US) | 2023-01-31 | — | — | US | disclosed |
| US-20220273555-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | ARES CAPITAL CORPORATION, AS AGENT | 2022-09-01 | — | — | US | disclosed |
| EP-4015005-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | ModernaTX, Inc. (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3978030-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | ModernaTX, Inc. (US) | 2022-04-06 | — | — | EP | disclosed |
| WO-2001038341-A1 | POLYNUCLEOTIDE LIGANDS AS ANTI-VIRAL AGENTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2001-05-31 | — | — | WO | disclosed |
| US-6184364-B1 | DEHYDRATING URIDINE TO FORM 2,2'-ANHYDROURIDINE, CONVERTING TO UNPROTECTED 2'-AZIDO-2'-DEOXYURIDINE, IODINATING TO FORM 5-IODO-2'-AZIDO, 2'-DEOXYURIDINE, THEN REDUCING TO 5-IODO, 2'-AMINO-2'-DEOXYURIDINE; SELEX LIGANDS | NEXSTAR PHARMACEUTICALS, INC. | 2001-02-06 | — | — | US | disclosed |
| US-5958691-A | DETECTION OF NUCLEIC ACID LIGANDS WITH MODIFIED NUCLEOTIDE TO TARGET GROUPS, SINGLE STRAND NUCLEIC ACIDS AND PARTITIONING THE NUCLEIC ACIDS, AMPLIFICATION | NEXSTAR PHARMACEUTICALS, INC. (US) | 1999-09-28 | — | — | US | disclosed |
| US-5817635-A | RNA MOLECULES WITH CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1998-10-06 | — | — | US | disclosed |
| US-5698687-A | RNA MOLECULE CONTAINING MODIFIED NUCLOSIDE | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-12-16 | — | — | US | disclosed |
| US-5672695-A | GENETIC ENGINEERED RNA MOLECULE, ATLEAST ONE MODIFIED NUCLEOSIDE HAVING A HALO, AMINO, MONO OR DISUBSTITUTED AMINO AND AZIDE MODIFIER GROUPS REPLACING HYDROXY GROUP AT 2' POSITION OF DRIBOSE SUGAR; SHOWS CATALYTIC ACTIVITY | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 1997-09-30 | — | — | US | disclosed |
| US-5660985-A | CONTACTING MIXTURE OF MODIFIED SINGLE-STRANDED NUCLEIC ACIDS WITH TARGET MOLECULE, PARTITIONING THOSE WITH INCREASED AFFINITY, AMPLIFYING TO IDENTIFY LIGANDS OF TARGET MOLECULE | NEXSTAR PHARMACEUTICALS, INC. (US) | 1997-08-26 | — | — | US | disclosed |
| EP-0552178-B1 | MODIFIED RIBOZYMES | MAX PLANCK GESELLSCHAFT (DE) | 1997-01-02 | — | — | EP | disclosed |
| EP-0552178-A1 | MODIFIED RIBOZYMES. | MAX PLANCK GESELLSCHAFT (DE) | 1993-07-28 | — | — | EP | disclosed |
| WO-1992007065-A1 | MODIFIED RIBOZYMES | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 1992-04-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240409597-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF SECRETED PROTEINS | MSH2, POLRMT, SARNP | P2RY2 2202/4885P2RY4 2575/4885P2RY6 1786/4885 |
| US-11564998-B2 | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins | PHAX, NSUN2, RNMT | P2RY2 2188/4885P2RY4 2571/4885P2RY6 2389/4885 |
| US-20260069717-A1 | MODIFIED NUCLEOSIDES, NUCLEOTIDES, AND NUCLEIC ACIDS, AND USES THEREOF | RNMT, RNGTT, NSUN2 | P2RY2 552/4885P2RY4 511/4885P2RY6 976/4885 |
| US-20250018062-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF BIOLOGICS AND PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLN, POLM | P2RY2 2758/4885P2RY4 2981/4885P2RY6 2558/4885 |
| US-20240131193-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF CYTOPLASMIC AND CYTOSKELETAL PROTEINS | PHAX, NSUN2, RNMT | P2RY2 2188/4885P2RY4 2571/4885P2RY6 2389/4885 |
| US-20250074962-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF ONCOLOGY-RELATED PROTEINS AND PEPTIDES | NSUN2, RNMT, NSUN3 | P2RY2 1684/4885P2RY4 1784/4885P2RY6 1593/4885 |
| US-20220273555-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF MEMBRANE PROTEINS | POLRMT, POLN, MSH2 | P2RY2 1489/4885P2RY4 1751/4885P2RY6 1367/4885 |
| US-20240327476-A1 | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS ASSOCIATED WITH HUMAN DISEASE | POLRMT, POLM, POLN | P2RY2 3235/4885P2RY4 3716/4885P2RY6 3234/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.